scholarly journals Vismodegib: First-in-Class Hedgehog Pathway Inhibitor for Metastatic or Locally Advanced Basal Cell Carcinoma

2014 ◽  
Vol 5 (4) ◽  
Author(s):  
Nancy M. Nix, PharmD, BCPS, BCOP ◽  
Olivia Burdine, PharmD ◽  
Makeda Walker, PharmD
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Locally Advanced ◽  
Hedgehog Pathway ◽  
Hedgehog Pathway Inhibitor ◽  
Advanced Basal Cell Carcinoma

Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma

2014 ◽  
Vol 71 (5) ◽  
pp. 1005-1008 ◽  
Author(s):  
Tjinta Brinkhuizen ◽  
Marie G. Reinders ◽  
Michel van Geel ◽  
Annelot J.L. Hendriksen ◽  
Aimée D.C. Paulussen ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Locally Advanced ◽  
Acquired Resistance ◽  
Hedgehog Pathway ◽  
Hedgehog Pathway Inhibitor ◽  
Advanced Basal Cell Carcinoma

scholarly journals Characterization and Management of Hedgehog Pathway Inhibitor‐Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

2016 ◽  
Vol 21 (10) ◽  
pp. 1218-1229 ◽  
Author(s):  
Mario E. Lacouture ◽  
Brigitte Dréno ◽  
Paolo Antonio Ascierto ◽  
Reinhard Dummer ◽  
Nicole Basset‐Seguin ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Hedgehog Pathway ◽  
Hedgehog Pathway Inhibitor ◽  
Advanced Basal Cell Carcinoma

scholarly journals Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib

2014 ◽  
Vol 70 (1) ◽  
pp. 60-69 ◽  
Author(s):  
Anne Lynn S. Chang ◽  
James A. Solomon ◽  
John D. Hainsworth ◽  
Leonard Goldberg ◽  
Edward McKenna ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Hedgehog Pathway ◽  
Expanded Access ◽  
Hedgehog Pathway Inhibitor ◽  
Advanced Basal Cell Carcinoma

scholarly journals Treatment of periocular advanced basal cell carcinoma with Hedgehog pathway inhibitors: a single-center study and a new dedicated therapeutic protocol

2021 ◽  
Author(s):  
Vincenzo De Giorgi ◽  
Luciana Trane ◽  
Giulia Pieretti ◽  
Nicola Santoro ◽  
Flavia Silvestri ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Locally Advanced ◽  
Delayed Diagnosis ◽  
Case Series ◽  
Hedgehog Pathway ◽  
Single Center ◽  
Management Protocol ◽  
Advanced Basal Cell Carcinoma

Background: The management of difficult-to-treat periocular basal cell carcinoma becomes very challenging in cases of delayed diagnosis, leading to the development of locally advanced basal cell carcinoma.Objective: The aim of this study was to evaluate the outcomes of Hedgehog pathway inhibitors (vismodegib and sonidegib)  treatment in patients affected by periocular locally advanced basal cell carcinoma. We focused on the common adverse events  and their correlation with the administration schedule  in order to determine a management protocol specific for the periocular area.Methods:  This observational prospective study included a single-center case series with patients who were histologically confirmed to have periocular or orbital locally advanced basal cell carcinoma,  treated with Hedgehog pathway inhibitors.Results: All patients benefitted in terms of regression or stabilization of the neoplasm. In the first months of treatment, the HPIs were well tolerated, and the first important side effects appeared after about 5 months of continuous use of the drug.Conclusion: These data could lead to a new type of therapeutic scheme where neoadjuvant therapy could be followed by pulse therapy as an adjuvant to surgery.

Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 9532-9532 ◽  
Author(s):  
Johan Hansson ◽  
Axel Hauschild ◽  
Rainer Kunstfeld ◽  
Jean Jacques Grob ◽  
Brigitte Dréno ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Hedgehog Pathway ◽  
Primary Analysis ◽  
Hedgehog Pathway Inhibitor ◽  
Advanced Basal Cell Carcinoma

scholarly journals High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature

Chemotherapy ◽  
2020 ◽  
Vol 65 (1-2) ◽  
pp. 2-10 ◽  
Author(s):  
Elena Campione ◽  
Monia Di Prete ◽  
Flavia Lozzi ◽  
Caterina Lanna ◽  
Giulia Spallone ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Locally Advanced ◽  
Indirect Comparison ◽  
Molecular Structures ◽  
Hedgehog Pathway ◽  
European Medicines Agency ◽  
Controlled Clinical Trial ◽  
Advanced Basal Cell Carcinoma

Basal cell carcinoma is the most common skin tumour, with the majority of the cases occurring on the head and neck district, where cosmetic and functional results are crucial. It can be locally destructive if not diagnosed early and treated appropriately. Surgery is the treatment of choice for most lesions, but aggressive, recurrent, or unresectable tumours can be challenging to manage. Advanced basal cell carcinoma includes high recurrence risk subtypes, in which standard therapies demonstrate lack of efficacy. This led to a need for investigating more deeply the pathogenesis of the disease and to the discovery of the implication of the hedgehog pathway. The development of systemic inhibitors of this pathway provides new treatment options for patients with advanced disease, resulting in survival improvement. Food and Drug Administration, before, and European Medicines Agency later approved 2 Hedgehog pathway inhibitors for the treatment of advanced basal cell carcinomas, vismodegib and sonidegib. Here, we present a review of the current English language literature trying to analyze differences in the 2 drugs as a head-to-head comparison between them has not already been documented in a randomized controlled clinical trial. Although vismodegib and sonidegib showed similar efficacy and safety profiles, in an indirect comparison scenario, sonidegib has shown slightly better outcomes in locally advanced basal cell carcinoma than vismodegib. They present different molecular structures, as they bind different residues on their targets and develop resistance for different mutations. In a future scenario, clinical trials comparing the 2 drugs are needed, as well as expanding data on discontinuation of therapy and/or consequential administration of them, with the aim to improve our clinical practise.

Sign in / Sign up

Export Citation Format

Share Document